On the SARS-CoV-2 vaccines developed by PRC and Germany - US

Report by : Gan Yung Chyan

                  / KUCINTA SETIA

The SARS-CoV-2 (covi, in short)  vaccine jointly developed by CanSino Biologics and the Chinese military research unit in Wuhan has shown that most volunteers had an immune response after receiving a dose of the vaccine. Side effects such as fever and pain at the injection site occurred in 77%, but they were not serious.

However, CanSino Bio’s covi vaccine test also shows that subjects who have been exposed to a specific adenovirus in the past have signs of a weakened immune response.

Another smaller trial by the German biotech company BioNTech and the American drugmaker Pfizer allows its covi vaccine to use ribonucleic acid (RNA) to instruct cells to make proteins similar to the outer surface of the coronavirus. The human body will recognize these virus-like proteins as foreign invaders, and then stimulate an immune response against the real virus.